Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population

PRODUCT LITERATURE

Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population

Reddy KR - Personal Name;

Hepatorenal syndrome-acute kidney injury (HRS-AKI) is associated with significant morbidity and mortality. While liver transplantation is the definitive treatment, continuous terlipressin infusion for HRS-AKI may provide benefit and, as such, was assessed in a population composed of candidates for liver transplant (LT). Fifty hospitalized LT-eligible patients with HRS-AKI received a single bolus followed by continuous terlipressin infusion. Acute-on-chronic liver failure grade 3, serum creatinine (SCr) > 5.0 mg/dL, or Model for End- Stage Liver Disease (MELD) ≥35 were exclusions.

Availability

Location name is not set Location name is not set

Terlipin-007

Available

Detail Information

Series Title: -
Call Number: -
Publisher: : .,
Collation: -
Language: English
ISBN/ISSN: -
Classification: NONE
Content Type: LITERATURE
Media Type: -
Carrier Type: -
Edition: -
Subject(s): Terlipin
Terlipressin infusion
Specific Detail Info: -
Statement of Responsibility: Liver Transplantation. 2024;30:1026–1038

Other version/related

No other version available

File Attachment

Read Here

Comments

You must be logged in to post a comment